Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company is finalizing the buildout and upgrades to its facilities and is preparing for the Grand Opening of CBIS’ first two Pre-ICO Pharmacies in California.
After the Grand Opening of the first two CBIS Pharmacies, the Company will announce the date for its 2018 Cannabis Science Black Tie Gala in Beverly Hills, California. The Gala will be – most importantly – an event to accumulate support for the eradication of critical ailments and improved palliative care in mainstream and distressed demographics. The program for the Cannabis Science Gala will include patient and physician testimonials, celebrity interests and accomplishments in the cannabinoid industry, new partnership announcements by Cannabis Science, and plenty of food and live entertainment.
The Cannabis Science Gala will be open to the Company's shareholders and stakeholders, and will include strategic partners, researchers, celebrities, and other interested parties. The CBIS Gala will be an opportunity for Cannabis Science to demonstrate the Company's appreciation for its shareholders, and to present shareholders and stakeholders an update on CBIS’ many upcoming and exciting initiatives including Mr. Dabney presenting the Shareholder Loyalty Gift Program.
The Company's shareholders and stakeholders will be able to learn firsthand about the work being done by Cannabis Science, and to help raise funds for awareness for cannabinoid-based pharmaceutical research.
“The buildout of our Pre ICO pharmacies is nearing finalization, and the training of our management and sales personnel is well underway,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “Our architects and construction team have exceeded our expectations for our Cannabis Science branded pharmacies. These flagship pharmacies will establish a corporate standard and serve as models as we acquire new pharmacies in California and eventually throughout the U.S.”
The CBIS Pharmacies will showcase the Cannabis Science Brand of high-quality Cannabinoid and Cannabis products and accessories for patients, doctors, and the consuming public. These products will range from pills, creams, extracts, sprays, tinctures, edibles, balms, patches, oils, raw products, and merchandise. The dispensaries will also showcase other brands as well, for patient continuity and familiarity.
CBIS’ first two pharmacies were selected due to their strategic locations. The CBIS Pharmacy on Pico Boulevard is in a classic Los Angeles corridor with continuous single-story retail. In Mid-City, Pico Boulevard has a healthy mixture of commercial and retail establishments. Pico Boulevard has a neighborhood-serving character, providing its many residents and visitors with easy access to its commercial and retail businesses.
The CBIS Pharmacy on Ventura Boulevard will benefit from being located on one of the primary east-to-west thoroughfares in the San Fernando Valley. Ventura Boulevard is one of the oldest routes in the San Fernando Valley, as it was originally a part of the El Camino Real (the trail between Spanish missions). Historically, local and small shops have concentrated and thrived along Ventura Boulevard. CBIS’ newly-designed pharmacies will compliment this historic area, adding to the pockets of housing, mini-malls, and shops, along with a wide assortment of businesses, schools, and other establishments. Residential property south of Ventura is considered to be among the most expensive in Los Angeles County, ranging from $2 million to $50 million, and this area is home to numerous celebrities, executives, athletes, and entertainers alike.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder